LTC3106463I2 - Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip trk kinazės slopikliai - Google Patents

Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip trk kinazės slopikliai

Info

Publication number
LTC3106463I2
LTC3106463I2 LTPA2020504C LTPA2020504C LTC3106463I2 LT C3106463 I2 LTC3106463 I2 LT C3106463I2 LT PA2020504 C LTPA2020504 C LT PA2020504C LT PA2020504 C LTPA2020504 C LT PA2020504C LT C3106463 I2 LTC3106463 I2 LT C3106463I2
Authority
LT
Lithuania
Prior art keywords
pyrasol
substituted
kinase inhibitors
pyrimidine compounds
trk kinase
Prior art date
Application number
LTPA2020504C
Other languages
English (en)
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41328903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC3106463(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of LTPA2020504I1 publication Critical patent/LTPA2020504I1/lt
Publication of LTC3106463I2 publication Critical patent/LTC3106463I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/02—Ergot alkaloids of the cyclic peptide type
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
LTPA2020504C 2008-10-22 2020-03-10 Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip trk kinazės slopikliai LTC3106463I2 (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10761608P 2008-10-22 2008-10-22
PCT/US2009/061519 WO2010048314A1 (en) 2008-10-22 2009-10-21 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
EP09740245.7A EP2350071B1 (en) 2008-10-22 2009-10-21 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
EP13197815.7A EP2725028B1 (en) 2008-10-22 2009-10-21 Substituted pyrazolo[1,5-]pyrimidine compounds as intermediates in the synthesis of TRK kinase inhibitors

Publications (2)

Publication Number Publication Date
LTPA2020504I1 LTPA2020504I1 (lt) 2020-03-25
LTC3106463I2 true LTC3106463I2 (lt) 2021-06-25

Family

ID=41328903

Family Applications (4)

Application Number Title Priority Date Filing Date
LTEP13197815.7T LT2725028T (lt) 2008-10-22 2009-10-21 Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip tarpiniai junginiai trk kinasės slopiklių sintezėje
LTEP18151233.6T LT3372605T (lt) 2008-10-22 2009-10-21 Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai
LTEP16166461.0T LT3106463T (lt) 2008-10-22 2009-10-21 Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai
LTPA2020504C LTC3106463I2 (lt) 2008-10-22 2020-03-10 Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip trk kinazės slopikliai

Family Applications Before (3)

Application Number Title Priority Date Filing Date
LTEP13197815.7T LT2725028T (lt) 2008-10-22 2009-10-21 Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip tarpiniai junginiai trk kinasės slopiklių sintezėje
LTEP18151233.6T LT3372605T (lt) 2008-10-22 2009-10-21 Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai
LTEP16166461.0T LT3106463T (lt) 2008-10-22 2009-10-21 Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai

Country Status (38)

Country Link
US (11) US8513263B2 (lt)
EP (4) EP2350071B1 (lt)
JP (5) JP5600111B2 (lt)
KR (5) KR102037619B1 (lt)
CN (2) CN103509017B (lt)
AR (2) AR074052A1 (lt)
AU (1) AU2009308465B2 (lt)
BR (1) BRPI0919873B8 (lt)
CA (1) CA2741313C (lt)
CL (1) CL2011000880A1 (lt)
CO (1) CO6440551A2 (lt)
CR (1) CR20110261A (lt)
CY (4) CY1118199T1 (lt)
DK (4) DK3106463T6 (lt)
ES (4) ES2588504T3 (lt)
HR (3) HRP20211722T1 (lt)
HU (4) HUE030413T2 (lt)
IL (3) IL212341A0 (lt)
LT (4) LT2725028T (lt)
LU (1) LUC00150I2 (lt)
ME (1) ME03010B (lt)
MX (1) MX2011004204A (lt)
MY (1) MY169791A (lt)
NL (1) NL301033I2 (lt)
NO (2) NO3106463T3 (lt)
NZ (1) NZ592809A (lt)
PL (4) PL2350071T3 (lt)
PT (4) PT2350071E (lt)
RS (3) RS62869B1 (lt)
RU (1) RU2018131134A (lt)
SG (3) SG196855A1 (lt)
SI (4) SI2725028T1 (lt)
SM (2) SMT201800244T1 (lt)
TR (1) TR201807039T4 (lt)
TW (4) TWI639605B (lt)
UA (1) UA106054C2 (lt)
UY (1) UY32192A (lt)
WO (1) WO2010048314A1 (lt)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012116217A1 (en) * 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
AU2012256237B2 (en) 2011-05-13 2017-01-05 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
KR20140105508A (ko) 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
EP2834243B1 (en) * 2012-03-09 2018-04-25 Lexicon Pharmaceuticals, Inc. PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
WO2014078408A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
MY178262A (en) 2012-11-13 2020-10-07 Array Biopharma Inc Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078328A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
HRP20161613T1 (hr) 2012-11-13 2017-01-13 Array Biopharma, Inc. Tvari bicikličke ureje, tioureje, gvanidina i cijanogvanidina korisne za liječenje boli
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
PL3636649T3 (pl) 2014-01-24 2024-05-06 Turning Point Therapeutics, Inc. Diaryle makrocykliczne jako modulatory kinaz białkowych
RU2733405C2 (ru) * 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CA2949160C (en) 2014-05-15 2023-03-21 Array Biopharma Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
HUE061448T2 (hu) * 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
EP3227276B1 (en) 2014-12-02 2021-09-01 Ignyta, Inc. Combinations for the treatment of neuroblastoma
CA2971024C (en) * 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
EP3267996B1 (en) 2015-03-12 2020-11-11 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
JP6929231B2 (ja) * 2015-05-29 2021-09-01 イグナイタ インコーポレイテッド Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法
WO2016196671A1 (en) * 2015-06-01 2016-12-08 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
ES2864839T3 (es) 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
JP6917974B2 (ja) 2015-07-06 2021-08-11 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ジアリール大環状多形
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
FI3733187T3 (fi) 2015-07-21 2024-12-18 Turning Point Therapeutics Inc Kiraalinen diaryylimakrosykli ja sen käyttö syövän hoidossa
AU2016311426B2 (en) 2015-08-26 2021-05-20 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
MX2018006195A (es) 2015-11-19 2018-09-05 Blueprint Medicines Corp Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
BR112018012255A2 (pt) 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
ES2987474T3 (es) * 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
ES2836222T3 (es) * 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
BR112019001607A2 (pt) 2016-07-28 2019-04-30 Tp Therapeutics, Inc. inibidores macrocíclicos de quinases
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN108003161B (zh) * 2016-10-28 2020-10-09 正大天晴药业集团股份有限公司 神经营养因子酪氨酸激酶受体抑制剂
AU2017348826B2 (en) 2016-10-28 2021-12-02 Centaurus Biopharma Co., Ltd. Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
AU2018302170B2 (en) 2017-07-19 2024-02-29 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
EP3661935B1 (en) * 2017-08-11 2022-10-12 Teligene Ltd Substituted pyrazolopyrimidines useful as kinases inhibitors
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
DK3674307T3 (da) * 2017-08-23 2023-09-11 Chia Tai Tianqing Pharmaceutical Group Co Ltd Makrocyklus indeholdende aminopyrazol og pyrimidin og farmaceutisk sammensætning og anvendelse deraf
CN107556226B (zh) * 2017-09-21 2020-06-30 苏州明锐医药科技有限公司 一种拉曲替尼中间体的制备方法
CN107445879B (zh) * 2017-09-21 2020-07-24 苏州立新制药有限公司 拉曲替尼中间体的制备方法
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
WO2019089668A1 (en) 2017-10-31 2019-05-09 Teva Pharmaceuticals Usa, Inc. Salts and solid state forms of larotrectinib
TW201927790A (zh) * 2017-11-10 2019-07-16 美商安捷克斯製藥公司 作為trk激酶抑制劑之巨環化合物及其用途
CN107987082B (zh) * 2017-11-14 2019-09-20 苏州东南药业股份有限公司 一种Larotrectinib的制备方法及其中间体
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EA202091475A1 (ru) 2017-12-15 2020-09-09 Пирамид Байосайенсиз, Инк. ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
US11453672B2 (en) 2017-12-22 2022-09-27 Shenzhen Targetrx, Inc. Substituted pyrazolo[1,5-a]pyrimidines as tropomyosin receptor kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2019144885A1 (zh) 2018-01-23 2019-08-01 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
CN111511749B (zh) * 2018-01-30 2022-02-08 上海吉倍生物技术有限公司 具有大环分子结构的化合物及其用途
US11459332B2 (en) 2018-03-14 2022-10-04 Fochon Biosciences, Ltd. Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitors
CN110305138B (zh) * 2018-03-27 2021-04-23 海创药业股份有限公司 一种治疗癌症的化合物及其用途
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
CN112004975A (zh) 2018-03-30 2020-11-27 住友重机械工业株式会社 施工机械的驾驶支援系统、施工机械
WO2019206069A1 (zh) 2018-04-25 2019-10-31 北京普祺医药科技有限公司 一种二芳基巨环化合物、药物组合物以及其用途
CN110294761B (zh) * 2018-06-08 2020-09-08 南京雷正医药科技有限公司 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
CN110627812B (zh) * 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
US12109193B2 (en) 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
CA3109104A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Fluoro .beta.-carboline compounds
CA3108714A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Pyrrolo - dipyridine compounds
CN110857304B (zh) * 2018-08-24 2021-05-18 北京富龙康泰生物技术有限公司 Trk抑制剂、其制备方法和用途
JP7443373B2 (ja) 2018-09-03 2024-03-05 タイリガンド バイオサイエンス（シャンハイ）リミテッド 抗がん性薬物としてのｔｒｋ阻害剤
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN112955453B (zh) * 2018-09-29 2022-04-19 山东绿叶制药有限公司 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN111039947A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类蛋白受体激酶抑制剂的制备和应用
CN111171019A (zh) 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN111171020A (zh) 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN109232582B (zh) * 2018-11-28 2021-02-05 安礼特（上海）医药科技有限公司 拉洛替尼硫酸氢盐晶型及其制备和应用
CN111269233A (zh) * 2018-12-05 2020-06-12 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
CN109608464B (zh) * 2018-12-12 2021-09-24 上海健康医学院 一种放射性碘标记Larotrectinib化合物及其制备方法和应用
CN109705124B (zh) * 2018-12-14 2021-09-24 上海健康医学院 一种放射性氟标记Larotrectinib化合物及其制备方法
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111362946A (zh) * 2018-12-25 2020-07-03 上海度德医药科技有限公司 一种药物化合物及其组合物和应用
CN109942574B (zh) * 2019-01-11 2022-04-01 成都阿奇生物医药科技有限公司 天奇替尼及其制备方法和用途
CN109942582B (zh) * 2019-03-15 2020-12-01 上海健康医学院 一种靶向原肌球蛋白激酶trk融合蛋白的pet探针及其合成与应用
JP7209415B2 (ja) 2019-03-19 2023-01-20 セントラル チャイナ ノーマル ユニバーシティ ピラゾロピリミジン化合物、医薬組成物、及びその使用
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN111848626B (zh) * 2019-04-30 2021-11-30 江苏柯菲平医药股份有限公司 Trk激酶抑制剂及其用途
AU2020270303B2 (en) 2019-05-08 2023-09-07 Tyk Medicines, Inc. Compound used as kinase inhibitor and application thereof
US20200398978A1 (en) * 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
WO2021023858A1 (en) * 2019-08-08 2021-02-11 Université De Strasbourg TrkB POSITIVE ALLOSTERIC MODULATORS
CN110804059B (zh) * 2019-09-30 2024-03-12 郑州泰基鸿诺医药股份有限公司 氨基甲酸酯类化合物、药物组合物及其应用
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN112812118A (zh) * 2019-11-18 2021-05-18 上海轶诺药业有限公司 一类蛋白受体激酶抑制剂的制备和应用
CN111138437B (zh) * 2019-12-04 2021-03-05 杭州华东医药集团新药研究院有限公司 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021187878A1 (ko) * 2020-03-17 2021-09-23 제이투에이치바이오텍 주식회사 변이성 trk 융합 단백질 억제용 화합물, 이의 의약 용도 및 제조 방법
JP7767301B2 (ja) 2020-04-15 2025-11-11 ピラミッド バイオサイエンシズ インコーポレイテッド チロシン受容体キナーゼ阻害剤を調製する方法
CN113563343B (zh) * 2020-07-27 2022-05-24 杭州邦顺制药有限公司 取代的吡唑并[1,5-a]嘧啶化合物及其用途
CN114276352B (zh) * 2020-10-13 2026-03-31 上海健康医学院 一种碳-11标记Larotrectinib化合物及其制备方法
EP4274826A1 (en) * 2021-01-08 2023-11-15 IFM Due, Inc. Oxalamide compounds and compositions for treating conditions associated with sting activity
WO2022168115A1 (en) 2021-02-05 2022-08-11 Mylan Laboratories Limited A process for the preparation of larotrectinib or its salts
IT202100003887A1 (it) 2021-02-19 2022-08-19 Olon Spa Procedimento per la preparazione di larotrectinib ad elevato grado di purezza
WO2023083357A1 (zh) * 2021-11-15 2023-05-19 石药集团中奇制药技术（石家庄）有限公司 氮杂稠环酰胺类化合物的盐、其结晶形式及其用途
CN116003469B (zh) * 2022-03-23 2023-10-17 南京知和医药科技有限公司 嘧啶基抗病毒化合物的制备与使用方法
CN114907315B (zh) * 2022-05-17 2023-09-12 重庆医科大学 Selitrectinib中间体的合成方法
CN117343064B (zh) * 2022-07-05 2024-04-16 南京知和医药科技有限公司 一种具有抗病毒作用的嘧啶衍生物的制备与应用
WO2024023836A1 (en) 2022-07-27 2024-02-01 Mylan Laboratories Limited Polymorphic form of larotrectinib sulfate
JP2025532532A (ja) 2022-09-07 2025-10-01 蘇州朗睿生物医薬有限公司 大環状イミダゾ［１，２－ｂ］ピリダジン誘導体並びにその調製方法及び用途
EP4382529A1 (en) 2022-12-07 2024-06-12 Bayer Consumer Care AG A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride
WO2024242416A1 (ko) * 2023-05-22 2024-11-28 주식회사 셀러스 신규한 cdk7 억제 화합물 및 이의 용도
WO2025014639A2 (en) * 2023-07-07 2025-01-16 The Johns Hopkins University Neutral sphingomyelinase inhibitors

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017286A (en) 1909-03-01 1912-02-13 Du Pont Powder Co Apparatus for treating explosive powder.
US1001160A (en) 1910-04-05 1911-08-22 Paul A Otto Aerodrome.
US1004709A (en) 1910-05-20 1911-10-03 Albert E Yerkes Spraying device.
US1013712A (en) 1911-06-03 1912-01-02 Alfred D Williams Tie and rail-fastener.
NZ234143A (en) 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
GB9212308D0 (en) 1992-06-10 1992-07-22 Ici Plc Therapeutic compositions
ES2141916T3 (es) 1993-11-30 2000-04-01 Searle & Co Pirazolil-bencenosulfonamidas sustituidas para el tratamiento de la inflamacion.
US5430021A (en) 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
JPH1020683A (ja) 1996-07-05 1998-01-23 Fuji Xerox Co Ltd 画像形成装置
JP3898296B2 (ja) * 1996-08-28 2007-03-28 ポーラ化成工業株式会社 ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬
CA2285264A1 (en) 1997-04-25 1998-11-05 Michiyo Gyoten Condensed pyridazine derivatives, their production and use
GEP20043214B (en) 1999-01-21 2004-04-26 Bristol Myers Squibb Company Us Complex of Ras-Farnesyltransferase Inhibitor and Sulfobutylether-7- Beta – Cyclodextrin or 2-Hydroxypropyl- Beta – Cyclodextrina and Pharmaceutical Compositions Containing the Same
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6534085B1 (en) 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
ATE446366T1 (de) 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
GB0028575D0 (en) 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
IL156487A0 (en) 2000-12-22 2004-01-04 Astrazeneca Ab Carbazole derivatives and their use as neuropeptide y5 receptor ligands
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
DK1401498T3 (da) 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
EP1505068A4 (en) * 2002-04-23 2008-03-19 Shionogi & Co PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE
US7449488B2 (en) * 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
JP4024624B2 (ja) 2002-08-26 2007-12-19 富士通株式会社 半導体装置の製造方法及び製造装置
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004022561A1 (en) * 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
AU2003298942A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
GB0303910D0 (en) * 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US20070037150A1 (en) 2003-02-21 2007-02-15 The Johns Hopkins University Tyrosine kinome
JP2004277337A (ja) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
EP1615667A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
CA2523508A1 (en) 2003-04-28 2004-11-11 Galpharma Co., Ltd. Galectin 9-inducing factors
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EA009517B1 (ru) 2003-06-27 2008-02-28 Байер Кропсайенс Аг Пиразолопиримидины
CN102408483B (zh) 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
UA83881C2 (en) 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
CN1938311A (zh) 2004-03-30 2007-03-28 因特蒙公司 作为病毒复制抑制剂的大环化合物
JO3088B1 (ar) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
CA2598076A1 (en) * 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
AU2006227300B2 (en) 2005-03-21 2012-02-02 Eli Lilly And Company Imidazopyridazine compounds
JP2008540335A (ja) * 2005-04-27 2008-11-20 アストラゼネカ・アクチエボラーグ ピラゾリル・ピリミジン誘導体の疼痛治療における使用
EP1899323A2 (en) 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
CN100406650C (zh) 2005-06-05 2008-07-30 徐斌 一种抗特大变位的模块式梳型桥梁伸缩缝装置
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US20070025540A1 (en) 2005-07-07 2007-02-01 Roger Travis Call center routing based on talkativeness
AU2006276246B2 (en) 2005-07-25 2012-09-27 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
JP2009502734A (ja) * 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
US20070184117A1 (en) 2005-08-03 2007-08-09 Stephen Gregory Tocopheryl polyethylene glycol succinate powder and process for preparing same
US20070191306A1 (en) 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
EP1926734A1 (en) 2005-08-22 2008-06-04 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
EP1919979B2 (en) 2005-08-25 2017-03-29 Creabilis Therapeutics S.P.A. Polymer conjugates of k-252a and derivatives thereof
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070082900A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
CN101316847A (zh) 2005-10-06 2008-12-03 先灵公司 用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物
ES2356776T3 (es) 2005-10-11 2011-04-13 Intermune, Inc. Compuestos y métodos para inhibir la replicación del virus de la hepatitis.
CA2624772C (en) 2005-10-11 2011-11-29 Centre National De La Recherche Scientifique (Cnrs) Compounds and kits for the detection and the quantification of cell apoptosis
CA2626789A1 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
US20070166336A1 (en) 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
WO2007084815A2 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Substituted thienopyrimidine kinase inhibitors
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
BRPI0708615A2 (pt) 2006-03-07 2011-06-07 Array Biopharma Inc compostos de pirazol heterobicìclicos e métodos de uso
GB0606805D0 (en) 2006-04-04 2006-05-17 Novartis Ag Organic compounds
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW201345908A (zh) 2006-07-05 2013-11-16 Mitsubishi Tanabe Pharma Corp 吡唑并〔１，５-ａ〕嘧啶化合物
PE20080538A1 (es) 2006-08-04 2008-06-18 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso
US20100029619A1 (en) * 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
CN101522682A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
BRPI0718029A2 (pt) 2006-11-06 2013-11-26 Supergen Inc Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
US7820684B2 (en) 2007-03-01 2010-10-26 Supergen, Inc. Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US20080255153A1 (en) * 2007-03-28 2008-10-16 Biovitrum Ab (Publ) New compounds
EP2137184B1 (en) 2007-04-03 2013-05-08 Array Biopharma, Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
EP2152688A1 (en) 2007-05-04 2010-02-17 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
CA2687909C (en) 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
PH12013501594A1 (en) 2007-07-20 2014-05-12 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
BRPI0815370B8 (pt) 2007-08-10 2021-05-25 Regeneron Pharma anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica
US8129371B2 (en) 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
MX2010004494A (es) 2007-10-23 2010-08-30 Novartis Ag Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
MX2010005950A (es) 2007-11-28 2010-06-17 Schering Corp 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2712298C (en) 2008-01-17 2015-11-24 Irm Llc Improved anti-trkb antibodies
MX2010009222A (es) 2008-03-03 2010-09-28 Ucb Pharma Sa Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
KR100963051B1 (ko) 2008-03-14 2010-06-09 광동제약 주식회사 입자크기가 조절된 술포데히드로아비에트산을 함유한쓴맛이 저감된 경구용 액상 조성물
US20090275622A1 (en) 2008-04-30 2009-11-05 Prasoona Linga Nizatidine formulations
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
US8946226B2 (en) 2008-07-29 2015-02-03 Nerviano Medical Sciences S.R.L. Use of CDK inhibitor for the treatment of glioma
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
JP2012509859A (ja) 2008-11-24 2012-04-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 中皮腫の治療のためのｃｄｋ阻害物質
AU2010213578B2 (en) 2009-02-12 2015-01-29 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2515655B1 (en) 2009-12-21 2015-08-05 Samumed, LLC 1h-pyrazolo[3,4-beta]pyridines and therapeutic uses thereof
ES2594927T3 (es) 2010-02-18 2016-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para prevenir las metástasis cancerosas
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US8543395B2 (en) 2010-05-18 2013-09-24 Shazam Entertainment Ltd. Methods and systems for performing synchronization of audio with corresponding textual transcriptions and determining confidence values of the synchronization
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
JP5908466B2 (ja) 2010-06-09 2016-04-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｒａｆ及びｍｅｋ阻害剤に対する耐性を与えるｍｅｋ１変異
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
AU2012256237B2 (en) 2011-05-13 2017-01-05 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
AU2012339753A1 (en) 2011-11-14 2014-06-19 Tesaro, Inc. Modulating certain tyrosine kinases
KR20140105508A (ko) 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
TW201350479A (zh) 2012-04-26 2013-12-16 Ono Pharmaceutical Co Ｔｒｋ阻害化合物
EP2855460B1 (en) 2012-05-23 2017-11-08 Nerviano Medical Sciences S.r.l. Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
EP2866802B1 (en) 2012-06-28 2016-07-27 Johnson & Johnson Consumer Inc. Racecadotril liquid compositions
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
EP2689778A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
CA2882759C (en) 2012-08-31 2018-11-20 The Regents Of The University Of Colorado Detection of the ntrk1-mprip gene fusion for cancer diagnosis
US20140084039A1 (en) 2012-09-24 2014-03-27 Electro Scientific Industries, Inc. Method and apparatus for separating workpieces
JP2014082984A (ja) 2012-10-23 2014-05-12 Astellas Pharma Inc 新規ｎｔｒｋ２活性化変異の検出法
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
MY178262A (en) 2012-11-13 2020-10-07 Array Biopharma Inc Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
HRP20161613T1 (hr) 2012-11-13 2017-01-13 Array Biopharma, Inc. Tvari bicikličke ureje, tioureje, gvanidina i cijanogvanidina korisne za liječenje boli
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CN104822390A (zh) 2012-11-29 2015-08-05 耶达研究及发展有限公司 预防肿瘤转移、癌症治疗和预后及鉴定为推定转移抑制剂的试剂的方法
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
WO2014130975A1 (en) 2013-02-22 2014-08-28 Bastian Boris C Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets
WO2014134096A1 (en) 2013-02-27 2014-09-04 Oregon Health & Science University Methods of treating cancers characterized by aberrent ros1 activity
CN113337604A (zh) 2013-03-15 2021-09-03 莱兰斯坦福初级大学评议会 循环核酸肿瘤标志物的鉴别和用途
EP2971094B1 (en) 2013-03-15 2021-09-15 Novartis AG Biomarkers associated with brm inhibition
WO2014152777A2 (en) 2013-03-15 2014-09-25 Insight Genetics, Inc. Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors
CA2907152A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
CN105378110B (zh) 2013-04-17 2024-06-25 生命技术公司 与癌症相关的基因融合体和基因变异体
SG11201600055PA (en) 2013-07-11 2016-02-26 Betta Pharmaceuticals Co Ltd Protein tyrosine kinase modulators and methods of use
US10705087B2 (en) 2013-07-26 2020-07-07 Japanese Foundation For Cancer Research Detection method for NTRK3 fusion
EP3628749A1 (en) 2013-07-30 2020-04-01 Blueprint Medicines Corporation Ntrk2 fusions
AU2014340398A1 (en) 2013-10-24 2016-06-09 Georgetown University Methods and compositions for treating cancer
JPWO2015064621A1 (ja) 2013-10-29 2017-03-09 公益財団法人がん研究会 新規融合体及びその検出法
PL3636649T3 (pl) 2014-01-24 2024-05-06 Turning Point Therapeutics, Inc. Diaryle makrocykliczne jako modulatory kinaz białkowych
US9346788B2 (en) 2014-02-05 2016-05-24 VM Oncology, LLC TrkA receptor tyrosine kinase antagonists and uses thereof
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CA2949160C (en) 2014-05-15 2023-03-21 Array Biopharma Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
WO2015183837A1 (en) 2014-05-27 2015-12-03 Brian Haynes Compositions, methods, and uses related to ntrk2-tert fusions
US20170114415A1 (en) 2014-05-30 2017-04-27 The Regents Of The University Of Colorado, A Body Corporate Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
MX2017001302A (es) 2014-08-01 2017-10-11 Pharmacyclics Llc Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk.
TWI573794B (zh) 2014-08-18 2017-03-11 小野藥品工業股份有限公司 ＴｒＫ阻礙化合物之酸附加鹽
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
HUE061448T2 (hu) 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
CA2971024C (en) 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors
CN104672121B (zh) 2015-02-16 2017-10-24 上海华默西医药科技有限公司 2r‑(2,5‑二氟苯基)吡咯烷盐酸盐的制备方法
TW202523682A (zh) 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
JP6929231B2 (ja) 2015-05-29 2021-09-01 イグナイタ インコーポレイテッド Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法
WO2016196671A1 (en) 2015-06-01 2016-12-08 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
AU2015101722A4 (en) 2015-06-19 2016-05-19 Macau University Of Science And Technology Oncogenic ros1 and alk kinase inhibitor
US9782400B2 (en) 2015-06-19 2017-10-10 Macau University Of Science And Technology Oncogenic ROS1 and ALK kinase inhibitor
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
ES2864839T3 (es) 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
US20170224662A1 (en) 2016-01-22 2017-08-10 The Medicines Company Aqueous Formulations and Methods of Preparation and Use Thereof
TW201733580A (zh) 2016-03-11 2017-10-01 小野藥品工業股份有限公司 Ｔｒｋ抑制劑抵抗性的癌治療劑
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
US20210030737A1 (en) 2016-04-19 2021-02-04 Exelixis, Inc. Triple Negative Breast Cancer Treatment Method
ES2836222T3 (es) 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
WO2017201156A1 (en) 2016-05-18 2017-11-23 Duke University Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers

Also Published As

Publication number Publication date
KR20170116220A (ko) 2017-10-18
IL278119A (en) 2020-11-30
LT3372605T (lt) 2022-02-10
IL278119B (en) 2022-06-01
AU2009308465B2 (en) 2015-02-12
US8513263B2 (en) 2013-08-20
RS53247B (sr) 2014-08-29
CO6440551A2 (es) 2012-05-15
LUC00150I1 (lt) 2020-03-13
US10774085B2 (en) 2020-09-15
SI3106463T1 (en) 2018-08-31
SI2725028T1 (sl) 2016-10-28
ME03010B (me) 2018-10-20
JP6105008B2 (ja) 2017-03-29
CY1120260T1 (el) 2019-07-10
US20170114067A1 (en) 2017-04-27
EP2725028B1 (en) 2016-05-25
TWI670272B (zh) 2019-09-01
CA2741313C (en) 2018-12-04
UA106054C2 (uk) 2014-07-25
CR20110261A (es) 2011-06-09
US20150133429A1 (en) 2015-05-14
EP2350071B1 (en) 2014-01-08
CY2020006I2 (el) 2020-11-25
KR101634833B1 (ko) 2016-06-29
HUE030413T2 (en) 2017-05-29
IL247884B (en) 2020-10-29
IL247884A0 (en) 2016-11-30
HUE037716T2 (hu) 2018-09-28
US20150005499A1 (en) 2015-01-01
JP2016210816A (ja) 2016-12-15
CN103509017A (zh) 2014-01-15
KR101652189B1 (ko) 2016-08-29
TW201835086A (zh) 2018-10-01
PL3106463T6 (pl) 2020-07-27
RU2523544C2 (ru) 2014-07-20
AU2009308465A1 (en) 2010-04-29
US20110195948A1 (en) 2011-08-11
RU2011120345A (ru) 2012-11-27
RS62869B1 (sr) 2022-02-28
NO2020004I1 (no) 2020-03-10
HUE057625T2 (hu) 2022-05-28
RU2018131134A (ru) 2020-03-02
NO3106463T3 (lt) 2018-07-28
ES2456346T3 (es) 2014-04-22
CY2020006I1 (el) 2020-05-29
SMT201400153B (it) 2015-01-15
TWI577680B (zh) 2017-04-11
LT2725028T (lt) 2016-09-26
US20210002287A1 (en) 2021-01-07
BRPI0919873A2 (pt) 2019-02-05
HRP20180746T1 (hr) 2018-06-29
EP2725028A1 (en) 2014-04-30
US20140194403A1 (en) 2014-07-10
HUS000512I2 (hu) 2021-03-29
RU2014120150A (ru) 2015-11-27
UY32192A (es) 2011-05-31
TW201731848A (zh) 2017-09-16
PL3372605T3 (pl) 2022-03-07
PL2725028T3 (pl) 2016-12-30
KR101853026B1 (ko) 2018-04-27
CL2011000880A1 (es) 2011-07-08
CA2741313A1 (en) 2010-04-29
JP6431512B2 (ja) 2018-11-28
JP6788649B2 (ja) 2020-11-25
MY169791A (en) 2019-05-15
SG196855A1 (en) 2014-02-13
BRPI0919873B8 (pt) 2021-05-25
BRPI0919873B1 (pt) 2020-04-14
EP2350071A1 (en) 2011-08-03
CN102264736B (zh) 2013-08-14
CY1118199T1 (el) 2017-06-28
RS57221B2 (sr) 2020-08-31
US20180127427A1 (en) 2018-05-10
US20240132500A1 (en) 2024-04-25
JP2014177494A (ja) 2014-09-25
US11267818B2 (en) 2022-03-08
US20230234955A1 (en) 2023-07-27
PT2725028T (pt) 2016-08-31
JP2012506446A (ja) 2012-03-15
LTPA2020504I1 (lt) 2020-03-25
JP5832597B2 (ja) 2015-12-16
KR20180043851A (ko) 2018-04-30
JP2019034961A (ja) 2019-03-07
DK2350071T3 (en) 2014-03-24
ES2900243T3 (es) 2022-03-16
US9447104B2 (en) 2016-09-20
EP3372605B1 (en) 2021-11-03
SMT201800244T1 (it) 2018-07-17
US9676783B2 (en) 2017-06-13
EP3106463B3 (en) 2020-01-22
US10047097B2 (en) 2018-08-14
US8865698B2 (en) 2014-10-21
NZ592809A (en) 2012-09-28
JP2015214590A (ja) 2015-12-03
AR112833A2 (es) 2019-12-18
KR20110074617A (ko) 2011-06-30
TWI639605B (zh) 2018-11-01
HRP20140309T1 (hr) 2014-05-09
MX2011004204A (es) 2011-08-12
ES2588504T3 (es) 2016-11-03
IL212341A0 (en) 2011-06-30
AR074052A1 (es) 2010-12-22
HRP20211722T1 (hr) 2022-02-04
DK3372605T3 (da) 2021-11-22
US9127013B2 (en) 2015-09-08
HRP20180746T4 (hr) 2020-02-21
DK2725028T3 (en) 2016-09-05
EP3106463B1 (en) 2018-02-28
SI3372605T1 (sl) 2022-03-31
PL2350071T3 (pl) 2014-06-30
DK3106463T3 (en) 2018-06-06
PT3106463T (pt) 2018-05-18
CY1124923T1 (el) 2023-01-05
ES2669581T3 (es) 2018-05-28
LUC00150I2 (lt) 2021-02-15
CN102264736A (zh) 2011-11-30
WO2010048314A1 (en) 2010-04-29
US10005783B2 (en) 2018-06-26
KR20140129384A (ko) 2014-11-06
PT2350071E (pt) 2014-04-11
HK1160640A1 (en) 2012-08-10
HK1193101A1 (zh) 2014-09-12
US20160228441A1 (en) 2016-08-11
JP5600111B2 (ja) 2014-10-01
DK3106463T6 (da) 2020-02-24
SG10201900514RA (en) 2019-02-27
RU2018131134A3 (lt) 2021-12-23
SI2350071T1 (sl) 2014-05-30
TWI458729B (zh) 2014-11-01
RU2666367C2 (ru) 2018-09-07
KR20160104085A (ko) 2016-09-02
PT3372605T (pt) 2021-12-09
NL301033I2 (nl) 2020-04-15
LT3106463T (lt) 2018-06-25
TW201020253A (en) 2010-06-01
EP3106463A1 (en) 2016-12-21
TR201807039T4 (tr) 2018-06-21
SG10201914059WA (en) 2020-03-30
HUS2000006I1 (hu) 2020-04-28
EP3372605A1 (en) 2018-09-12
TW201500361A (zh) 2015-01-01
RS57221B1 (sr) 2018-07-31
ES2669581T7 (es) 2020-07-29
CN103509017B (zh) 2015-10-07
KR101784798B1 (ko) 2017-10-16
KR102037619B1 (ko) 2019-10-28
PL3106463T3 (pl) 2018-08-31
US20190211017A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
LTC3106463I2 (lt) Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip trk kinazės slopikliai
CY2024030I2 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
SI2350075T1 (sl) Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
DK2384326T3 (da) Pyrrolo[2,3-d]pyrimidinforbindelser
PL2610256T3 (pl) Pochodne pirymidyny jako inhibitory kinaz białkowych
EP2336123A4 (en) HETEROCYCLIC COMPOUND AS INHIBITOR OF PROTEIN KINASE
HK1150829A (en) Pyrimidine derivatives as kinase inhibitors
BRPI0906985A2 (pt) Derivados de pirido[4,3-d]pirimidinona como inibidores de cinase